| Name | Title | Contact Details |
|---|---|---|
Sophie Mukadam |
Chief Operating Officer | Profile |
Greffex™ is a privately held, multi-national company, headquartered in Aurora, Colorado. Established in 1999, Greffex has developed a novel genetic platform for the development and production of vaccines. Our proprietary GREVAX™ Universal Platform delivers vaccines in a faster, more affordable and more efficient manner. Once a pathogen has been identified, Greffex`s team designs and produces a GREVAX™ vaccine in as little as 4 weeks. The state-of-the-art flexibility of the GREVAX™ Universal Platform makes it the ideal delivery vehicle for vaccines against a wide variety of infectious disease, including but not limited to Pandemic Influenza strains, Anthrax and Dengue Fever, as well as Malaria, Hepatitis C, Respiratory Syncytial Virus (RSV), Ebola, HPV, Plague, Tuberculosis and a host of other vaccine candidates.
Founded in 2009, Celmatix is a personalized medicine company focused on fertility and women’s health. Our technology-enabled products empower people, through better data, to dramatically improve their chances of conceiving.
Pulmotect has developed PUL-042, an inhaled therapeutic which aims to boost the body`s innate immune system resulting in highly-targeted lung protection against all major classes of pathogens including bacteria, fungi, and viral pathogens.
Greiner Bio One Inc is a Monroe, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TARA pioneers predictive tissue models that enable faster, safer, and more reliable development of new medicines. Treatments can make it to market more rapidly, enabling better health and longer life for people.